Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities

Mol Pharm. 2023 Aug 7;20(8):3698-3740. doi: 10.1021/acs.molpharmaceut.2c01080. Epub 2023 Jul 24.


Human viral oncogenesis is a complex phenomenon and a major contributor to the global cancer burden. Several recent findings revealed cellular and molecular pathways that promote the development and initiation of malignancy when viruses cause an infection. Even, antiviral treatment has become an approach to eliminate the viral infections and prevent the activation of oncogenesis. Therefore, for a better understanding, the molecular pathogenesis of various oncogenic viruses like, hepatitis virus, human immunodeficiency viral (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), and Epstein-Barr virus (EBV), could be explored, especially, to expand many potent antivirals that may escalate the apoptosis of infected malignant cells while sparing normal and healthy ones. Moreover, contemporary therapies, such as engineered antibodies antiviral agents targeting signaling pathways and cell biomarkers, could inhibit viral oncogenesis. This review elaborates the recent advancements in both natural and synthetic antivirals to control viral oncogenesis. The study also highlights the challenges and future perspectives of using antivirals in viral oncogenesis.

Keywords: Antiviral Agents; Malignancy; Oncoviruses; Therapeutics; Viral Oncogenesis.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Carcinogenesis
  • Epstein-Barr Virus Infections* / drug therapy
  • Herpesvirus 4, Human
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Neoplasms* / prevention & control


  • Antiviral Agents